Monte Rosa Therapeutics, Inc. (GLUE) Fundamental Analysis: Bull vs. Bear Case

GLUE

Monte Rosa Therapeutics, Inc.

Fundamental data last updated:August 17, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

VALUATION

P/E

-9.78

Market Cap ($M USD)

$1.26B

Forward P/E

-12.29

PEG

-0.60

PRICE TO SALES

29.40 PRICE TO BOOK

2.44 EV / EBITDA

-8.16

5-Year Average P/E

Free Cash Flow Yield

-1.56%

DCF Value

$23.63

Graham Number

N/A

Price to FCF

-64.24

EV to FCF

-58.10

Earnings Yield

-10.23%

FCF Yield

-1.56%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$1.98

Next Year EPS Growth Estimate

-$1.58

Next Year Revenue Growth Estimate

$173.87M

Return on Equity (ROE)

-40.99%

FREE CASH FLOW

Operating Margin

-345.21%

Debt-to-Equity

0.17 Piotroski F-Score

3 Altman Z-Score

2.83 Return on Invested Capital (ROIC)

-22.28%

Current Ratio

9.54 Quick Ratio

9.54 Net Debt to EBITDA

0.86 Interest Coverage

0.00 Gross Profit margin

95.28%

FCF PER SHARE

$-0.30

REVENUE PER SHARE

$0.66

Gainseekers Quantitative Analysis

Summary

Monte Rosa Therapeutics, Inc. is trading at a valuation that suggests the market is skeptical about its near-term prospects. The stock’s price has been below its DCF value, indicating potential undervaluation. However, with a Forward P/E of -12.29 and an Earnings Yield of -10.23%, the company is not generating profits, raising concerns about its financial health. The Altman Z-score of 2.92 suggests moderate financial distress, but not imminent bankruptcy. Overall, the market seems to be pricing in significant risk, possibly overlooking its long-term potential.

AI Exposure / Tech Reliance

Operating within the biotechnology sector, Monte Rosa Therapeutics is inherently positioned to leverage AI advancements in drug discovery and development. The industry's rapid adoption of AI tools for precision medicine could enhance its R&D efficiency. However, the company's current financial metrics do not yet reflect a strong adaptation to these technological shifts.

The Bull Case

For value or GARP investors, Monte Rosa Therapeutics presents a compelling opportunity due to its low Debt/Equity ratio of 0.17, indicating prudent financial management. The high Current Ratio of 9.54 suggests robust liquidity, providing a cushion for future investments. Despite a negative ROIC of -22.28%, the company's ability to maintain a Gross Profit Margin of 95.28% hints at strong pricing power in its niche. These factors, combined with a Buy consensus rating, may attract investors looking for long-term growth potential.

The Bear Case

The stock faces significant structural risks, primarily due to its high Price/Sales ratio of 29.40, which signals overvaluation relative to its revenue. The negative Free Cash Flow Yield and Price to FCF ratio of -64.24 highlight severe cash flow issues, raising red flags about its operational efficiency. Additionally, with an Operating Margin of -345.21%, the company is bleeding cash, which could be unsustainable in the long run. The stock's proximity to its 52-week high further suggests it might be technically overextended.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$31.75

Institutional Ownership %

1-Year Beta

1.62 Insider Buying % (6 Mo)

Distance to 52-Week High

32.90%

Distance to 52-Week Low

79.89%

EARNINGS SURPRISE %

-60.71%

50-DAY SMA

$18.17

200-DAY SMA

$14.85

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.